Date of Award

4-22-2025

Document Type

Independent Study

Degree Name

Master of Science in Nursing (MSN)

Department

Nursing

Program Affiliation

Family Nurse Practitioner (FNP)

First Advisor

Dr. Jody Goard

Abstract

Background: Treatment options for SUDs fail to address the neurobiological underpinnings of addiction. Recent studies suggest that GLP-1s, including semaglutide, liraglutide, and exenatide, offer therapeutic benefits by reducing cravings, improving treatment adherence, and decreasing relapse rates across a range of SUDs, including alcohol, cannabis, cocaine, nicotine, and opioid use disorders.

Purpose: The purpose of this article is to explore studies that highlight the potential benefits of GLP-1 receptor agonists in reducing substance cravings, improving treatment adherence, and decreasing relapse rates for patients with various SUDs.

Methods: A comprehensive review of recent studies examining the effects of GLP-1 receptor agonists, including semaglutide, liraglutide, and exenatide, was conducted. These studies evaluate the impact of GLP-1s on craving reduction, treatment adherence, and relapse rates in patients with SUDs, focusing on various SUDs.

Results: The findings suggest that GLP-1 receptor agonists are effective in reducing cravings and substance consumption, particularly for alcohol and opioids, and potentially nicotine and cannabis. The evidence supports the role of GLP-1s in influencing neurobiological pathways related to reward processing, mood, and cognition, leading to improvements in addiction treatment outcomes.

Implications for Practice: GLP-1s should be considered in collaboration with addiction specialists and mental health professionals. FNPs can educate patients about the benefits of these medications, support treatment adherence, and advocate for improved access to them. Continued research and patient-centered care will be crucial for integrating GLP-1 receptor agonists into clinical practice to manage SUDs.

Download

Included in

Nursing Commons

Share

COinS